Genmab — April 2020
-
Research on Acute Myeloid Leukemia (AML) Therapeutics Market (impact of COVID-19) 2020-2026: Novartis, Roche, Genmab https://redandblackonline.com/research-on-acute-myeloid-leukemia-aml-therapeutics-market-impact-of-covid-19-2020-2026-novartis-roche-genmab/
-
I thought this was interesting in the Halo shareholder letter under SC benefits "The ability to facilitate the administration of treatment in lower cost settings such as the physician office or the community setting. Janssen, as an example, has stated DARZALEXÒ SC supports their strategy to seek to expand treatment into the community setting." https://www.halozyme.com/letter-to-shareholders/
-
Helt enig GB markedet forventer påvirkning. Se efter triggere.
-
God morgen.
-
consensus for dara Q1 sales = USD 902M
-
i can get you one at $783 million
https://au.news.yahoo.com/j-js-pharma-unit-perform-160104494.html -
Consensus for 20 analysts. From Bloomberg. I can't link.
-
Sydinvest / Jefferies https://www.sydinvest.dk/nyheder.aspx?Action=1&NewsId=117772&PID=9258
-
Some rumours among brokers that a partner deal could include more products than Epcoritamab
-
Hvor læser du de rygter?
-
Men det er besemt ikke unormalt med aftaler der dækker flere stoffer/targets
-
det kan jeg ikke disclose, og som sagt så er det rygter....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind